Eric Topol

physician-scientist, author of SUPER AGERS Ground Truths:

[Eric Topol @EricTopol]

A new cover for SUPER AGERS after making the NYT bestseller list. Thanks to you for making it the #1 ranked new non-fiction book on Amazon.
https://t.co/2LU5uH821R

[Eric Topol @EricTopol]

Chronic air pollution exposure (even moderate) and more advanced coronary artery disease
https://t.co/wvbqSwQSHk

[Eric Topol @EricTopol]

No, the peptide craze is not backed by science.
"What people are shooting up with out there I would give to mice."
“The influencer crowd has sort of created this perception that these are miracle drugs."— @mkaeberlein
New feature @nature
https://t.co/o0CHojoFNj

[Eric Topol @EricTopol]

Reducing brain tumor diagnosis from 12 days to 12 minutes with AI.
Predicting methylation pattern from path slides.
Outperformed 5 neuropathologists @NatureCancer @MoritzGerstung
https://t.co/9hetQkGhLq

[Eric Topol @EricTopol]

A review of the effects of marathon running on the heart
https://t.co/argjLSDkMO
including release of blood biomarkers cardiac troponin, NT-proBNP without known clinical significance

[Eric Topol @EricTopol]

On the front page @nytimes today, by @SteveLohr
https://t.co/EOF9QYAE7B

[Eric Topol @EricTopol]

The pro-inflammatory role of microglia is considered a key driver of Alzheimer's disease. Today @NeuroCellPress discovery of an epigenetic regulator of microglial mitochondria in the experimental model that may be amenable as a target for therapy or prevention
https://t.co/NXkEi59H8N

[Eric Topol @EricTopol]

AI of radiologist read as normal mammograms shown to detect high-risk of breast cancer out several years
"Artificial intelligence scores from sequential
mammograms in individuals diagnosed with breast cancer showed elevated scores up to 10 years before diagnosis"
a retrospective study, but supported by prospective study in 3-5 year time horizon
https://t.co/NafnAkpEfo
https://t.co/ead144H2XW

[Eric Topol @EricTopol]

And plans to do this at the whole-body level
@techreview
What could go wrong? Inducing cancer, for one.
https://t.co/goNOht9Qct

[Eric Topol @EricTopol]

The first participant to receive partial cellular reprogramming for eye disease (advanced glaucoma) in a pilot study of 12 patients was treated. Using 3 of the 4 Yamanaka stem cell factors to potentially achieve cellular rejuvenation @Nature
https://t.co/R4oJlrPhnS

[Eric Topol @EricTopol]

The conclusions of this report are in stark contrast to last week's exhaustive review.
https://t.co/xOitXMEX2P

[Eric Topol @EricTopol]

Finings of an exhaustive review of alcohol effects on 20 health outcomes from 843 studies
https://t.co/Xnzg1LGpGp
—"Current evidence does not support a universally
applicable threshold for alcohol consumption that maximizes health for all."
Associations:
—Increased risk of 10 cancers, pancreatitis, cirrhosis, tuberculosis, atrial fibrillation, pneumonia
—Decreased risk of ischemic heart disease, Type 2 diabetes, Alzheimer's disease, ischemic and hemorraghic stroke (with low-moderate intake)
"Our findings should not be interpreted as endorsing alcohol consumption for health benefits."

[Eric Topol @EricTopol]

The suppressed report that concluded there is no protective or safe level of alcohol consumption, now published. It was commissioned by US Congress
Report https://t.co/XmmsSo9q3q
Editorial https://t.co/8NuqBwkugM
"Despite the study’s adherence to its mandate, its findings were sidelined.”

[Eric Topol @EricTopol]

Link https://t.co/hzETCP8Iny

[Eric Topol @EricTopol]

A sodium-glucose cotransporter 2 drug (SGLT2) was linked to >80% reduction of hospitalization for heart failure in people who carried a disease-causing (pathogenic or likely pathogenic) genomic variant.
Compared with placebo in a randomized trial with subsequent exome sequencing in Type 2 diabetes
A striking KM event graph (Figure)

[Eric Topol @EricTopol]

In today's @TheLancet there are 3 papers on cardiometabolic disease: biology, epidemiology, prevention/treatment.
The sobering and all to common story from womb to tomb conveyed in this graphic
https://t.co/rVs2Yz97NC
https://t.co/OpuJTia0bC
https://t.co/i714onXoCG

[Eric Topol @EricTopol]

A new book by @helenpearson — BEYOND BELIEF— takes us through an 8-decade progression for what is the now considered best medical evidence. Our conversation gets into some incredible historical examples, such as sudden infant death syndrome.
In the new Ground Truths. A @NotebookLM infographic on some of the book content below

[Eric Topol @EricTopol]

Preserving lean mass during tirzepatide (Zepbound) treatment. A randomized trial of a myostatin inhibitor for muscle mass building shows proof-of-concept.
A 55% retention of lean mass compared with placebo
https://t.co/urw9Gvy11L just published @NatureMedicine

[Eric Topol @EricTopol]

@paulg Unclear, Paul. I only see results for the 13 cancers known to have an association with obesity, but not on other types.

[Eric Topol @EricTopol]

GLP-1 drugs in people with obesity (no diabetes) and the link to reduction of cancer
Among nearly 230,000 individuals, there was >40% overall reduction in 13 cancers associated with obesity with just 2 years of follow-up. Not proof of cause and effect, but consistent with many recent reports on the link between GLP-1 drugs with less cancer
https://t.co/X1P9xe8z2O

[Eric Topol @EricTopol]

To be clear on the 3 different peptides:
—Semaglutide (Ozempic) is GLP-1 only
—Tirzepatide (Zepbound) is GLP-1 + GIP (Glucose-dependent Insulinotropic Polypeptide, formerly aka gastric inhibitory polypeptide)
—New ones published today are GLP-1 and glucagon
—Animal data on GIP and glucagon, none clinical

[Eric Topol @EricTopol]

The tide is coming in. High tide of the X-tides, that is in the new GLP-1 family of peptide drugs. Today @NEJM survodutide, a GLP-1 and glucagon dual receptor agonist (no GIP, like tirzepatide) drug that achieved ~16% body weight loss at 2 different doses cf placebo
https://t.co/lHCy7iLUCn

[Eric Topol @EricTopol]

And today @JAMA_current Mazdutide, also a GLP-1 and glucagon dual receptor agonist with similar body weight loss as Survodutide https://t.co/BLLVmXgUp8